Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8593569 | 1.00 | MEN1 (0.59) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL27982703 | 0.92 | KMT2A (0.54) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL3529478 | 0.84 | SLC6A3 (0.56) | MEN1KMT2AMAPTALDH1A1NPC1 | |
| SCHEMBL2874789 | 0.84 | SLC6A3 (0.52) | MEN1KMT2AMAPTALDH1A1NPC1 | |
| SCHEMBL4053767 | 0.83 | MAPT (0.56) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL1345434 | 0.83 | KMT2A (0.56) | MEN1KMT2AMAPTSLC6A3GAA | |
| SCHEMBL1345244 | 0.83 | KMT2A (0.56) | MEN1KMT2AMAPTSLC6A3GAA | |
| SCHEMBL427393 | 0.83 | KMT2A (0.56) | MEN1KMT2AMAPTSLC6A3GAA | |
| SCHEMBL8805132 | 0.81 | SLC6A3 (0.50) | MEN1KMT2AMAPTALDH1A1NPC1 | |
| SCHEMBL521125 | 0.81 | SLC6A3 (0.50) | MEN1KMT2AMAPTALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302968-A1 | RADIATION CLEAVED DRUG-CONJUGATE LINKERS ENABLE LOCAL PAYLOAD RELEASE SCLEROSIS | THE GENERAL HOSPITAL CORPORATION | 2025-10-02 | — | — | US | disclosed |
| WO-2025078841-A2 | ANTIBODIES, CONJUGATES, AND USES THEREOF | ANTIKOR BIOPHARMA LIMITED (GB) | 2025-04-17 | — | — | WO | disclosed |
| EP-4522139-A1 | RADIATION CLEAVED DRUG-CONJUGATE LINKERS ENABLE LOCAL PAYLOAD RELEASE SCLEROSIS | The General Hospital Corporation (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2024210154-A1 | ANTIBODY-FUNCTIONAL SUBSTANCE CONJUGATE, ANTIBODY DERIVATIVE, AND COMPOUND, OR SALTS THEREOF | 味の素株式会社 | 2024-10-10 | — | — | WO | disclosed |
| WO-2023220280-A1 | RADIATION CLEAVED DRUG-CONJUGATE LINKERS ENABLE LOCAL PAYLOAD RELEASE SCLEROSIS | THE GENERAL HOSPITAL CORPORATION (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-4237008-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | Elucida Oncology, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
| WO-2022093800-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2015038426-A1 | SELF-IMMOLATIVE LINKERS CONTAINING MANDELIC ACID DERIVATIVES, DRUG-LIGAND CONJUGATES FOR TARGETED THERAPIES AND USES THEREOF | ASANA BIOSCIENCES, LLC (US) | 2015-03-19 | — | — | WO | disclosed |
| US-8158618-B2 | Dibenzothiazepine derivatives and uses thereof—424 | ASTRAZENECA AB (SE) | 2012-04-17 | — | — | US | disclosed |
| US-8158618-B2 | Dibenzothiazepine derivatives and uses thereof—424 | ASTRAZENECA AB (SE) | 2012-04-17 | — | — | US | disclosed |
| CN-102127091-A | Heterocyclic ring-containing schiff base compound | TIANJIN INST PHARM RESEARCH | 2011-07-20 | — | — | CN | disclosed |
| US-20110160184-A1 | Dibenzothiazepine Derivatives and Use Thereof | ASTRAZENECA AB (SE) | 2011-06-30 | — | — | US | disclosed |
| US-20110160184-A1 | Dibenzothiazepine Derivatives and Use Thereof | ASTRAZENECA AB (SE) | 2011-06-30 | — | — | US | disclosed |
| US-20090318415-A1 | DIBENZOTHIAZEPINE DERIVATIVES AND USES THEREOF - 424 | ASTRAZENECA AB (SE) | 2009-12-24 | — | — | US | disclosed |
| US-20090318415-A1 | DIBENZOTHIAZEPINE DERIVATIVES AND USES THEREOF - 424 | ASTRAZENECA AB (SE) | 2009-12-24 | — | — | US | disclosed |
| WO-2009154563-A1 | DIBENZOTHIAZEPINE DERIVATIVES AND USE THEREOF | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | disclosed |
| US-20040214798-A1 | Nitroaryl phosphoramide compositions and methods for targeting and inhibiting undesirable cell growth or proliferation | HU, LONGQIN | 2004-10-28 | — | — | US | disclosed |
| EP-0816316-A1 | PROCESS FOR PRODUCING 1,2-ETHANEDIOL DERIVATIVES | NITTO CHEMICAL INDUSTRY CO., LTD. (JP) | 1998-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302968-A1 | RADIATION CLEAVED DRUG-CONJUGATE LINKERS ENABLE LOCAL PAYLOAD RELEASE SCLEROSIS | HIF1A, HIF1AN, DCLRE1A | MEN1 381/4885KMT2A 2082/4885MAPT 834/4885 |
| US-20090318415-A1 | DIBENZOTHIAZEPINE DERIVATIVES AND USES THEREOF - 424 | DRD4, DRD2, GABBR1 | MEN1 2691/4885KMT2A 743/4885MAPT 237/4885 |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | MEN1 2314/4885KMT2A 4146/4885MAPT 668/4885 |
| US-20110160184-A1 | Dibenzothiazepine Derivatives and Use Thereof | DRD2, DRD4, GABBR1 | MEN1 2365/4885KMT2A 814/4885MAPT 166/4885 |
| US-20040214798-A1 | Nitroaryl phosphoramide compositions and methods for targeting and inhibiting undesirable cell growth or proliferation | MKI67, NME2, NTPCR | MEN1 1914/4885KMT2A 1459/4885MAPT 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.